JP2022502359A5 - - Google Patents
Info
- Publication number
- JP2022502359A5 JP2022502359A5 JP2021514556A JP2021514556A JP2022502359A5 JP 2022502359 A5 JP2022502359 A5 JP 2022502359A5 JP 2021514556 A JP2021514556 A JP 2021514556A JP 2021514556 A JP2021514556 A JP 2021514556A JP 2022502359 A5 JP2022502359 A5 JP 2022502359A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- agent according
- administered
- ulcers
- subject
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077313A JP2025125558A (ja) | 2018-09-17 | 2025-05-07 | 皮膚科障害の処置のための薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194930.6 | 2018-09-17 | ||
| EP18194930 | 2018-09-17 | ||
| EP18203665.7 | 2018-10-31 | ||
| EP18203665 | 2018-10-31 | ||
| PCT/EP2019/074767 WO2020058217A1 (en) | 2018-09-17 | 2019-09-17 | Agent for treatment of dermatological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077313A Division JP2025125558A (ja) | 2018-09-17 | 2025-05-07 | 皮膚科障害の処置のための薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502359A JP2022502359A (ja) | 2022-01-11 |
| JP2022502359A5 true JP2022502359A5 (https=) | 2022-09-28 |
| JPWO2020058217A5 JPWO2020058217A5 (https=) | 2022-09-28 |
Family
ID=67989007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514556A Pending JP2022502359A (ja) | 2018-09-17 | 2019-09-17 | 皮膚科障害の処置のための薬剤 |
| JP2025077313A Pending JP2025125558A (ja) | 2018-09-17 | 2025-05-07 | 皮膚科障害の処置のための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077313A Pending JP2025125558A (ja) | 2018-09-17 | 2025-05-07 | 皮膚科障害の処置のための薬剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220064243A1 (https=) |
| EP (1) | EP3852785A1 (https=) |
| JP (2) | JP2022502359A (https=) |
| KR (1) | KR20210061388A (https=) |
| CN (1) | CN113226350B (https=) |
| AU (1) | AU2019343514B2 (https=) |
| BR (1) | BR112021003820A2 (https=) |
| CA (1) | CA3111158A1 (https=) |
| MA (1) | MA53636A (https=) |
| MX (1) | MX2021002983A (https=) |
| WO (1) | WO2020058217A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023536229A (ja) * | 2020-07-27 | 2023-08-24 | ヒューマン セル カンパニー | Ｎｇｆバリアント、産生、組成物、及び治療的使用 |
| CA3207296A1 (en) * | 2021-01-06 | 2022-07-14 | The Penn State Research Foundation | Methods and materials for treating hair loss |
| US12268677B2 (en) | 2022-04-27 | 2025-04-08 | The Penn State Research Foundation | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| EP1482966B1 (en) | 2002-03-12 | 2014-05-14 | Bio-Click Technologies Ltd | Method and composition for treating skin wounds with epidermal growth factor |
| ITRM20060367A1 (it) * | 2006-07-13 | 2008-01-14 | Lay Line Genomics Spa | Muteine del hngf usi terapeutici e composizioni farmaceutiche |
| WO2010128519A1 (en) | 2009-05-04 | 2010-11-11 | Kumar C Jairaj | A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| US20180086805A1 (en) * | 2016-05-20 | 2018-03-29 | Chiesi Farmaceutici S.P.A. | proNGF mutants and uses thereof for the preparation of NGF mutants |
-
2019
- 2019-09-17 JP JP2021514556A patent/JP2022502359A/ja active Pending
- 2019-09-17 CA CA3111158A patent/CA3111158A1/en active Pending
- 2019-09-17 KR KR1020217011307A patent/KR20210061388A/ko not_active Ceased
- 2019-09-17 BR BR112021003820-5A patent/BR112021003820A2/pt unknown
- 2019-09-17 CN CN201980060757.0A patent/CN113226350B/zh active Active
- 2019-09-17 MA MA053636A patent/MA53636A/fr unknown
- 2019-09-17 WO PCT/EP2019/074767 patent/WO2020058217A1/en not_active Ceased
- 2019-09-17 MX MX2021002983A patent/MX2021002983A/es unknown
- 2019-09-17 US US17/277,240 patent/US20220064243A1/en not_active Abandoned
- 2019-09-17 AU AU2019343514A patent/AU2019343514B2/en active Active
- 2019-09-17 EP EP19769794.9A patent/EP3852785A1/en active Pending
-
2025
- 2025-03-28 US US19/093,959 patent/US20250277010A1/en active Pending
- 2025-05-07 JP JP2025077313A patent/JP2025125558A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Groves et al. | Recombinant human GM-CSF in the treatment of poorly healing wounds | |
| JP2022502359A5 (https=) | ||
| JP2001519786A (ja) | 創傷治癒用医薬の製造のためのオキシトシン活性を有する物質の使用 | |
| TWI587867B (zh) | 用於促進傷口癒合之短生物活性肽 | |
| Kwon et al. | Current and emerging topical scar mitigation therapies for craniofacial burn wound healing | |
| CN104602699B (zh) | 含c‑肽的用于预防或治疗糖尿病性血管生成损伤的组合物 | |
| KR20080031405A (ko) | 상피 재생의 촉진 | |
| RU2506092C2 (ru) | Способ активирования лечения ран | |
| CN108135965A (zh) | 用于伤口愈合的含p物质的药物组合物 | |
| JP5300281B2 (ja) | 創傷治療剤および創傷治療用組成物 | |
| US20220168207A1 (en) | Compositions and methods of use for treatment or improvement of the condition and appearance of skin | |
| JPWO2020058217A5 (https=) | ||
| KR101303299B1 (ko) | 항균 펩타이드의 피부 세포 재생 촉진제로서의 신규한 용도 | |
| CN112423772A (zh) | Rps2肽调节内皮细胞功能障碍的用途 | |
| TW202228667A (zh) | 慢性傷口癒合之二組分組合物 | |
| EP3173066A1 (en) | Plaster comprising antiedematous substances for the treatment of bruising and injury | |
| Liu et al. | The therapeutic effects of basic fibroblast growth factor in nasal vestibulitis | |
| WO2020016155A1 (en) | Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias | |
| KR20210024015A (ko) | 상처 치유에 사용하기 위한 루브리신 | |
| HK40091784A (zh) | 治疗伤口的组合物和方法 | |
| WO2012126047A1 (en) | Agent and method for treating pain and reducing inflammation | |
| Zhang et al. | Effect of rhGM-CSF in promoting wound healing via macrophage immunomodulation | |
| Akgül et al. | Contemporary redox-related therapeutic approach to burn wounds in the elderly | |
| Shepard | The Impact of Diabetes Mellitus on Burns and Standard Burn Treatments | |
| Moncrief | Burns: II. Initial treatment |